Inactive Instrument

Neos Therapeutics, Inc.

NEOS

US64052L1061

Neos Therapeutics, Inc. Announces Resignation of Thomas Mcdonnell as Chief Commercial Officer

November 30, 2018 at 06:00 pm IST

Neos Therapeutics, Inc. announced that in connection with the realignment, the company announced that its Chief Commercial Officer, Thomas McDonnell, resigned upon mutual agreement with the company effective immediately.

Latest news about Neos Therapeutics, Inc.

Aytu Biopharma, Inc. Enters into Loan and Security Agreement, by and Among Neos Therapeutics, Inc., Neos Therapeutics Brands, Llc, Neos Therapeutics, Lp, Neos Therapeutics Commercial, Llc, Pharmafab Texas, Llc, Aytu Therapeutics, Llc, Innovus Pharmaceuticals, Inc., Semprae Laboratories, Inc., Novalere, Inc., Supplement Hunt, Inc., and Delta Prime Savings Club, Inc. as Borrowers	31/22/31	CI
Aytu BioScience : Completes Merger With Neos Therapeutics	22/21/22	MT
Neos Therapeutics, Inc. Announces Board Changes	22/21/22	CI
Neos Therapeutics, Inc. Announces Cessation of Richard Eisenstadt as Chief Financial Officer	22/21/22	CI
Neos Therapeutics, Inc. Announces Cessation of Gerald Mclaughlin as Chief Executive Officer	22/21/22	CI
Neos Therapeutics, Inc.(NasdaqGM:NEOS) dropped from S&P TMI Index	22/21/22	CI
Neos Therapeutics, Inc.(NasdaqGM:NEOS) dropped from NASDAQ Composite Index	19/21/19	CI
Aytu BioScience, Inc. completed the acquisition of Neos Therapeutics, Inc..	19/21/19	CI
Transcript : Neos Therapeutics, Inc. - Shareholder/Analyst Call	18/21/18
Neos Therapeutics : Merger With Aytu BioScience Endorsed by Proxy Advisers Glass, Lewis	12/21/12	MT
Aytu BioScience : Neos Therapeutics Shareholders To Vote on Deal In March	10/21/10	MT
Neos Therapeutics, Inc. announced that it has received $5 million in funding from Aytu BioScience, Inc.	08/21/08	CI
DJ Industrial : Wall Street Slips Pre-Bell as Stimulus Impasse Drags, Jobless Claims Surge	10/20/10	MT
Neos Therapeutics : Aytu BioScience and Neos Therapeutics Enter Definitive Merger Deal	10/20/10	MT
Transcript : Aytu BioScience, Inc., Neos Therapeutics, Inc. - M&A Call	10/20/10
Aytu BioScience, Inc. entered into definitive merger agreement to acquire Neos Therapeutics, Inc. for $37.8 million.	10/20/10	CI
Neos Therapeutics, Inc. announced that it expects to receive $5 million in funding from Aytu BioScience, Inc.	10/20/10	CI
Transcript : Neos Therapeutics, Inc., Q3 2020 Earnings Call, Nov 09, 2020	09/20/09
Neos Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	09/20/09	CI
Transcript : Neos Therapeutics, Inc., Q2 2020 Earnings Call, Aug 10, 2020	10/20/10
Neos Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	10/20/10	CI
Neos Therapeutics, Inc.(NasdaqGM:NEOS) dropped from Russell Microcap Growth Index	26/20/26	CI
Neos Therapeutics, Inc.(NasdaqGM:NEOS) dropped from Russell Microcap Index	26/20/26	CI
Neos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	12/20/12	CI
Transcript : Neos Therapeutics, Inc., Q1 2020 Earnings Call, May 11, 2020	12/20/12

Chart Neos Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Neos Therapeutics, Inc. is a commercial-stage pharmaceutical company. The Company is focused on developing and manufacturing central nervous system (CNS) focused products. The Company markets Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate) and Adzenys-ER (amphetamine), all for the treatment of attention deficit hyperactivity disorder (ADHD). The Company manufactures and markets a generic Tussionex (hydrocodone and chlorpheniramine) (generic Tussionex), for the treatment of cough and upper respiratory symptoms of a cold. It is also developing N-desethyloxybutynin (NT0502), for the treatment of sialorrhea in patients with neurological conditions. NT0502 is a selective anticholinergic agent that is developing an oral, treatment to reduce chronic sialorrhea in patients with neurological conditions associated with salivation and drooling.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+38.51%	73TCr
NOVO NORDISK A/S	+33.05%	60TCr
JOHNSON & JOHNSON	-6.23%	35TCr
MERCK & CO., INC.	+18.78%	33TCr
ABBVIE INC.	+1.35%	28TCr
ASTRAZENECA PLC	+16.00%	24TCr
NOVARTIS AG	+8.09%	20TCr
ROCHE HOLDING AG	-5.77%	20TCr
AMGEN INC.	+6.19%	16TCr

Other Pharmaceuticals